▴ The thiazolidinedione rosiglitazone and the biguanide metformin are effective antihyperglycaemic agents with different modes of action; rosiglitazone primarily increases insulin sensitivity, whereas metformin primarily reduces hepatic glucose output.
▴ Antihyperglycaemic combination therapy is often required to achieve effective glycaemic control. A fixed-dose formulation of rosiglitazone/metformin was recently approved in the EU and the US for the treatment of type 2 diabetes mellitus in patients inadequately controlled on metformin monotherapy.
▴ Bioequivalence between the fixed-dose combination tablet and coadministration of rosiglitazone with metformin at the same dosage has been established in a pharmacokinetic study.
▴ Fixed-dose rosiglitazone/metformin 8mg/2g per day reduced glycosylated haemoglobin (HbA1c) and fasting plasma glucose (FPG) levels to a significantly greater extent than metformin 3 g/day in patients with type 2 diabetes in a 24-week, randomised, double-blind study.
▴ Rosiglitazone plus metformin was significantly more effective than metformin alone at reducing HbA1c and FPG levels in patients with type 2 diabetes in three 26-week, randomised, double-blind, placebo-controlled studies.
▴ Rosiglitazone plus metformin was generally well tolerated in all studies and had a tolerability profile similar to that of metformin monotherapy. Mild or moderate symptomatic hypoglycaemia was reported in ≤4.4% of rosiglitazone plus metformin recipients.
Metformin Rosiglitazone Glycaemic Control HbA1c Level Sulfonylurea
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.
Hawkins D, Bradberry JC, Cziraky MJ, et al. National Pharmacy Cardiovascular Council treatment guidelines for the management of type 2 diabetes mellitus: toward better patient outcomes and new roles for pharmacists. Pharmacotherapy 2002 Apr; 22(4): 436–44PubMedCrossRefGoogle Scholar
Wagstaff AJ, Goa KL. Rosiglitazone: a review of its use in the management of type 2 diabetes mellitus. Drugs 2002; 62(12): 1805–37PubMedCrossRefGoogle Scholar
American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2005; 28 Suppl. 1: S37–42CrossRefGoogle Scholar
Dunn CJ, Peters DH. Metformin: a review of its pharmacological properties and therapeutic use in non-insulin-dependent diabetes mellitus. Drugs 1995 May; 49(5): 721–49PubMedCrossRefGoogle Scholar
Cox SL. Rosiglitazone maleate/metformin hydrochloride: a new formulation therapy for type 2 diabetes. Drugs Today (Barc) 2004 Jul; 40(7): 633–43CrossRefGoogle Scholar
Vanderpoel DR, Hussein MA, Watson-Heidari T, et al. Adherence to a fixed-dose combination of rosiglitazone maleate/ metformin hydrochloride in subjects with type 2 diabetes mellitus: a retrospective database analysis. Clin Ther 2004 Dec; 26(12): 2066–75PubMedCrossRefGoogle Scholar
Del Prato S, Volpe L. Rosiglitazone plus metformin: combination therapy for type 2 diabetes. Expert Opin Pharmacother 2004; 5(6): 1411–22PubMedCrossRefGoogle Scholar
Diamant M, Heine RJ. Thiazolidinediones in type 2 diabetes mellitus: current clinical evidence. Drugs 2003; 63(13): 1373–405PubMedCrossRefGoogle Scholar
Bailey CJ, Day C. Avandamet: combined metformin-rosiglitazone treatment for insulin resistance in type 2 diabetes. Int J Clin Pract 2004 Sep; 58(9): 867–76PubMedCrossRefGoogle Scholar
Karlsson HKR, Hällsten K, Björnholm M, et al. Effects of metformin and rosiglitazone treatment on insulin signaling and glucose uptake in patients with newly diagnosed type 2 diabetes: a randomized controlled study. Diabetes 2005 May; 54(5): 1459–67PubMedCrossRefGoogle Scholar
Shargorodsky M, Wainstein G, Gavish E, et al. Treatment with rosiglitazone reduces hyperinsulinemia and improves arterial elasticity in patients with type 2 diabetes mellitus. Am J Hypertens 2003 Aug; 16(8): 617–22PubMedCrossRefGoogle Scholar
Ovalle F, Bell DSH. Effect of rosiglitazone versus insulin on the pancreatic β-cell function of subjects with type 2 diabetes. Diabetes Care 2004 Nov; 27(11): 2585–9PubMedCrossRefGoogle Scholar
Lupi R, Del Guerra S, Marselli L, et al. Rosiglitazone prevents the impairment of human islet function induced by fatty acids: evidence for a role of PPARγ2 in the modulation of insulin secretion. Am J Physiol Endocrinol Metab 2004 Apr; 286(4): E560–7PubMedCrossRefGoogle Scholar
Tiikkainen M, Häkkinen A-M, Korsheninnikova E, et al. Effects of rosiglitazone and metformin on liver fat content, hepatic insulin resistance, insulin clearance, and gene expression in adipose tissue in patients with type 2 diabetes. Diabetes 2004 Aug; 53(8): 2169–76PubMedCrossRefGoogle Scholar
Haffner SM, Greenberg AS, Weston WM, et al. Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Circulation 2002 Aug 6; 106(6): 679–84PubMedCrossRefGoogle Scholar
Marx N, Froehlich J, Siam L, et al. Antidiabetic PPARγ-activator rosiglitazone reduces MMP-9 serum levels in type 2 diabetic patients with coronary artery disease. Arterioscler Thromb Vasc Biol 2003 Feb; 23: 283–8PubMedCrossRefGoogle Scholar
Marx N, Imhof A, Froehlich J, et al. Effect of rosiglitazone treatment on soluble CD40L in patients with type 2 diabetes and coronary artery disease. Circulation 2003 Apr 22; 107: 1954–7PubMedCrossRefGoogle Scholar
Yosefy C, Magen E, Kiselevich A, et al. Rosiglitazone improves, while glibenclamide worsens blood pressure control in treated hypertensive diabetic and dyslipidemic subjects via modulation of insulin resistance and sympathetic activity. J Cardiovasc Pharmacol 2004 Aug; 44(2): 215–22PubMedCrossRefGoogle Scholar
Sarafidis PA, Lasaridis AN, Nilsson PM, et al. Ambulatory blood pressure reduction after rosiglitazone treatment in patients with type 2 diabetes and hypertension correlates with insulin sensitivity increase. J Hypertens 2004 Sep; 22(9): 1769–77PubMedCrossRefGoogle Scholar
Natali A, Baldeweg S, Toschi E, et al. Vascular effects of improving metabolic control with metformin or rosiglitazone in type 2 diabetes. Diabetes Care 2004 Jun; 27(6): 1349–57PubMedCrossRefGoogle Scholar
Honisett SY, Stojanovska L, Sudhir K, et al. Rosiglitazone lowers blood pressure and increases arterial compliance in postmenopausal women with type 2 diabetes [letter]. Diabetes Care 2003 Nov; 26(11): 3194–5PubMedCrossRefGoogle Scholar
Regensteiner JG, Bauer TA, Reusch JB. Rosiglitazone improves exercise capacity in type 2 diabetes (T2DM) [abstract no. 35-OR]. Diabetes 2004 Jun; 53 Suppl. 2: A8–9Google Scholar
Petrofsky JS, Bweir SO, Lee SW, et al. Rosiglitazone improves age related reductions in forearm resting flows and endothelial dysfunction observed in type 2 diabetes [abstract no. P3022]. Eur Heart J 2004; 25 (Abstr. Suppl.): 512–3Google Scholar
Fonseca V, Rosenstock J, Patwardhan R, et al. Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: a randomized controlled trial. JAMA 2000 Apr 5; 283(13): 1695–702PubMedCrossRefGoogle Scholar
Gómez-Perez FJ, Fanghänel-Salmón G, Antonio Barbosa J, et al. Efficacy and safety of rosiglitazone plus metformin in Mexicans with type 2 diabetes. Diabetes Metab Res Rev 2002; 18: 127–34PubMedCrossRefGoogle Scholar
GlaxoSmithKline. Avandamet® (rosiglitazone maleate and metformin hydrochloride) tablets [online]. Available from URL: http://us.gsk.com [Accessed 2005 May 4]
Zarich SW. Treating the diabetic patient: appropriate care for glycemic control and cardiovascular disease risk factors. Rev Cardiovasc Med 2003; 4 Suppl. 6: S19–8PubMedGoogle Scholar
Sivitz WI. Lipotoxicity and glucotoxicity in type 2 diabetes: effects on development and progression. Postgrad Med 2001 Apr; 109(4): 55–9, 63-4PubMedCrossRefGoogle Scholar
Lupi R, Del Guerra S, Fierabracci V, et al. Lipotoxicity in human pancreatic islets and the protective effect of metformin. Diabetes 2002 Feb; 51 Suppl. 1: S134–7PubMedCrossRefGoogle Scholar
Weissman PN, Goldstein BJ, Campbell JC, et al. Rosiglitazone plus metformin combination effects on CV risk markers suggest potential CV benefits in type 2 diabetic patients [abstract no. 121-OR]. Diabetes 2004 Jun; 53 Suppl. 2: 28Google Scholar
Derosa G, Gaddi AV, Piccinni MN, et al. Antithrombotic effects of rosiglitazone-metformin versus glimepiride-metformin combination therapy in patients with type 2 diabetes mellitus and metabolic syndrome. Pharmacotherapy 2005 May; 25(5): 637–45PubMedCrossRefGoogle Scholar
Bakris GL, Ruilope LM, Weston WM, et al. Rosiglitazone (RSG) added to metformin (MET) reduces urinary albumin/ creatinine ratio and ambulatory blood pressure in subjects with microalbuminuria and type 2 diabetes (T2DM) [abstract no. 543-P]. Diabetes 2005 Jun; 54 Suppl. 1: A134Google Scholar
Di Cicco RA, Allen A, Carr A, et al. Rosiglitazone does not alter the pharmacokinetics of metformin. J Clin Pharmacol 2000 Nov; 40(11): 1280–5Google Scholar
Cox PJ, Ryan DA, Hollis FJ, et al. Absorption, disposition, and metabolism of rosiglitazone, a potent thiazolidinedione insulin sensitizer, in humans. Drug Metab Dispos 2000 Jul; 28(7): 772–80PubMedGoogle Scholar
Stewart M, Bailey C, Andrew D, et al. Rosiglitazone/metformin (RSG/MET) fixed dose combination (AVM) is associated with attainment of glycaemic targets for a greater proportion of patients with type 2 diabetes (T2DM) than uptitrated MET. Diabet Med 2005; 22 Suppl. 2: 48. Plus poster presented at the Diabetes UK Annual Professional Conference; 2005 Apr 20–22; GlasgowGoogle Scholar
Rosenstock J, Stow L, Rood J, et al. Rosiglitazone/metformin (RSG/MET) fixed dose combination (FDC) is effective and well-tolerated in drug-naive type 2 diabetes mellitus (T2DM) subjects with severe hyerglycemia [abstract no. 515-P]. Diabetes 2005 Jun; 54 Suppl. 1: A127Google Scholar
Maheux P, Berry RA, Warsi G, et al. Rosiglitazone-metformin combination improves glycemic control in patients with type 2 diabetes [poster no. 168]. 5th Annual Professional Conference of the Canadian Diabetes Association and the Canadian Society of Endocrinology and Metabolism CDA/CSEM; 2001 Oct 17–20; Edmonton, 168Google Scholar
Garber A, Sankoh S, Mohideen P, et al. Glyburide/metformin tablets versus metformin plus rosiglitazone in type 2 diabetes patients uncontrolled on metformin: attaining glycemic goals [abstract no. 513-P]. Diabetes 2003 Jun; 52 Suppl. 1: 119–20. Plus poster presented at the 63rd Annual Scientific Sessions of the American Diabetes Association; 2003 Jun 13–17; New OrleansGoogle Scholar
Home PD, Pocock S, Beck-Nielsen H, et al. Rosiglitazone evaluated for cardiac outcomes and regulation of glycaemia in diabetes (RECORD): an interim analysis of glycaemia at 18 months [poster no. 725]. 40th Annual Meeting of the European Association for the Study of Diabetes; 2004 Sep 5–9; MunichGoogle Scholar